Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine.

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Abstract Text:

C Härnryd,L Bjerkenstedt,K Björk,B Gullberg,G Oxenstierna,G Sedvall,F A Wiesel,G Wik,A Aberg-Wistedt,

To evaluate the clinical potential of sulpiride for the treatment of schizophrenic patients, a double-blind study was performed comparing fixed doses of sulpiride (800 mg daily) and chlorpromazine (400 mg daily). Twenty-five schizophrenic (RDC) patients participated in each treatment group. Antipsychotic effects were evaluated by CPRS and NOSIE ratings before and after 1, 2, 4 and 8 weeks of treatment. Interrater reliabilities for CPRS items and subscales were satisfactory. Treatment with sulpiride or chlorpromazine resulted in a significant reduction of psychotic morbidity as estimated by CPRS and global ratings. CPRS scores reflecting autism were significantly reduced in all ratings of sulpiride-treated patients, but only after four weeks in the chlorpromazine group. Total NOSIE scores indicated improvement in both treatment groups. A significant difference in favour of sulpiride was obtained for the NOSIE subscale "retardation". Extrapyramidal side effects occurred at a similar frequency in both treatment groups. Autonomic side effects occurred to a greater extent in chlorpromazine-treated patients. Lactation was reported only in four sulpiride-treated patients. Liver transaminase enzymes in serum were markedly elevated only in chlorpromazine-treated patients. The results indicate that sulpiride has a marked antipsychotic effect which is at least not inferior to that of chlorpromazine. A better effect on autistic components of behaviour was demonstrated for sulpiride. The results indicate a higher risk of lactation but a lower risk of anticholinergic side effects and liver toxicity for treatment with sulpiride than with chlorpromazine.

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Publishing Authors By Initials

C Härnryd,L Bjerkenstedt,K Björk,B Gullberg,G Oxenstierna,G Sedvall,FA Wiesel,G Wik,A Aberg-Wistedt,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME: 311

Page Numbers: 7-30

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 1984

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Information

Substance Name: Chlorpromazine

Registry Number: 50-53-3

Grant and Affiliation Information for Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine.

AFFILIATION:

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine Related Publications

• Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine.
• Platelet serotonergic functions and light therapy in seasonal affective disorder.
• The antidepressant effects of 5-HT uptake inhibitors.